If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal bloating, you may be concerned about gastroparesis—a condition where stomach emptying slows. Decades of pharmacovigilance have documented gastrointestinal side effects with GLP-1 receptor agonists, and recent case reports highlight delayed gastric emptying as a potential concern. This page reviews the patterns reported in medical literature to help you understand the evidence.
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in some formulations, for weight loss. Its pharmacological action includes slowing gastric emptying, which is a known mechanism that can contribute to gastrointestinal adverse effects. Among the most serious of these is gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, abdominal pain, and early satiety. Clinical presentation and diagnosis of gastroparesis typically involve a history of persistent nausea, vomiting, postprandial fullness, and abdominal discomfort. Diagnosis is confirmed through gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may lead to complications such as malnutrition, dehydration, and electrolyte imbalances. Evidence from clinical trials and post-marketing surveillance indicates a clear association between Ozempic use and gastrointestinal adverse reactions, including those consistent with gastroparesis. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis and may reflect underlying delayed gastric emptying.
Post-marketing data from the FDA Adverse Event Reporting System (FAERS) further highlight the association. Among the most frequently reported adverse events for Ozempic are nausea (8652 reports), vomiting (5578 reports), diarrhea (5274 reports), and impaired gastric emptying (2693 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). The presence of 'impaired gastric emptying' as a distinct reported term underscores the clinical recognition of this adverse effect. The mechanistic pathway linking Ozempic to gastroparesis involves its action as a GLP-1 receptor agonist. GLP-1 receptors are expressed in the gastrointestinal tract, and activation slows gastric emptying by inhibiting antral contractions and stimulating pyloric tone. While this effect is intended to improve glycemic control by reducing postprandial glucose excursions, it can become pathological in some patients, leading to symptomatic gastroparesis. The risk may be dose-dependent, as suggested by the higher incidence of gastrointestinal adverse reactions with higher doses. Regarding the adequacy of warnings, the prescribing information for Ozempic includes gastrointestinal adverse reactions in the label, but it does not explicitly list gastroparesis as a separate warning or contraindication. The label notes that gastrointestinal adverse reactions are common and that discontinuation due to these reactions occurred in a small percentage of patients. However, the term 'impaired gastric emptying' is not highlighted as a specific risk in the label's boxed warning or precautions section. This may leave patients and healthcare providers unaware of the potential for a serious, chronic condition like gastroparesis to develop.
For affected patients in Texas, attorney-related considerations are important. Individuals who have developed gastroparesis after using Ozempic may have legal grounds to seek compensation for medical expenses, lost wages, pain and suffering, and other damages. Key factors in such cases include the timeline between exposure and documented harm. Gastroparesis symptoms often emerge during dose escalation or after prolonged use, and the condition may persist even after discontinuation of the drug. Medical records documenting the onset of symptoms, diagnostic tests confirming delayed gastric emptying, and a temporal relationship to Ozempic use are critical evidence. Patients should consult with an attorney experienced in pharmaceutical litigation to evaluate the strength of their case. The attorney will review the adequacy of warnings provided by the manufacturer, the patient's medical history, and the specific circumstances of the injury. In Texas, product liability claims may be based on theories of defective design, failure to warn, or negligence. In summary, the evidence from clinical trials and post-marketing surveillance demonstrates a clear association between Ozempic use and gastrointestinal adverse reactions, including impaired gastric emptying consistent with gastroparesis. The mechanistic basis for this effect is well understood, and the risk appears dose-related. While the drug's label acknowledges gastrointestinal adverse reactions, it does not provide explicit warnings about gastroparesis. Patients who have suffered this condition should seek medical evaluation and legal counsel to understand their options.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying. This mechanism can lead to gastrointestinal adverse effects, including gastroparesis—a condition of delayed gastric emptying. Clinical trials show higher rates of nausea, vomiting, and impaired gastric emptying in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Post-marketing data from FAERS also report thousands of cases of impaired gastric emptying (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC).
If you developed gastroparesis after using Ozempic, seek medical evaluation for proper diagnosis and treatment. Document your symptoms, medication history, and any diagnostic tests (e.g., gastric emptying scintigraphy). Consult a Texas Ozempic gastroparesis attorney to evaluate potential legal claims for compensation based on failure to warn or defective design.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.